Overview
US consumer healthcare firm's Q4 revenue fell 5% yr/yr, missing analyst expectations
Adjusted EPS for Q4 missed analyst expectations
Company to acquire LaCorium Health, an Australian therapeutic skin care company
Outlook
Company sees fiscal 2027 revenue of $1.1 bln to $1.121 bln
Prestige expects fiscal 2027 organic revenue growth of 1% to 3%
Company forecasts fiscal 2027 adjusted diluted EPS of $4.42 to $4.51
Result Drivers
EYE & EAR CARE SUPPLY CONSTRAINTS - Co said lower Eye & Ear Care category sales, driven by limited ability to supply demand for Clear Eyes, weighed on Q4 revenue
SHIPPING DISRUPTIONS - Q4 international segment revenue was hurt by shipping disruptions in the Middle East
PRIOR YEAR ORDER TIMING - Accelerated order timing in the prior year's Q4 created a headwind for current quarter revenue
Company press release: ID:nGNX9cCjPt
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$281.62 mln
$293.66 mln (7 Analysts)
Q4 Adjusted EPS
Miss
$1.23
$1.39 (7 Analysts)
Q4 Net Income
$53.93 mln
Q4 Gross Profit
$146.30 mln
Q4 Operating Expenses
$70.81 mln
Q4 Operating Income
$75.49 mln
Q4 Pretax Profit
$64.77 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc is $78.00, about 54.7% above its May 12 closing price of $50.41
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 13 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)